Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Frontline Acalabrutinib Plus Venetoclax/Obinutuzumab Shows Promising Activity in CLL

September 29th 2021

The frontline triplet combination comprised of acalabrutinib, venetoclax, and obinutuzumab proved to be highly active and well tolerated when used in the treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda on the Safety and Efficacy Results of the TRANSCEND CLL 004 Trial in CLL

September 23rd 2021

William G. Wierda, MD, PhD, discusses the safety and efficacy results of the phase 1/2 TRANSCEND CLL 004 trial in chronic lymphocytic leukemia.

Acalabrutinib, Alone or With Obinutuzumab, Improves Quality-Adjusted Survival in Frontline CLL

September 22nd 2021

Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Thompson on the Results of the BRUIN Study in Patients With Richter's Transformation

September 21st 2021

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

Dr. Robak on the Results of the 7-Year Follow-Up of RESONATE-2 in CLL

September 21st 2021

Tadeusz Robak, MD, PhD, discusses the results of the 7-year follow-up analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. John Byrd Presented the Binet-Rai Medal Award at XIX International Workshop on Chronic Lymphocytic Leukemia

September 21st 2021

During the XIX International Workshop on Chronic Lymphocytic Leukemia, which occurred virtually 17-20 September, Dr. John Byrd was presented the Binet-Rai Medal Award for his outstanding findings, which led to the use of BTK Inhibitors in almost every phase of CLL therapy.

U2 Plus Pembrolizumab Shows Continued Efficacy at 5 Years in CLL and Richter’s Transformation

September 20th 2021

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

Dr. Wierda on the Fixed-Duration Cohort Results of CAPTIVATE Trial in CLL

September 20th 2021

William G. Wierda, MD, PhD, discusses the fixed-duration cohort results of the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Dr. Ailawadhi on the Results of a First-in-Human Study of Lisaftoclax in Hematologic Malignancies

September 20th 2021

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

PAK1 Emerges as a Potential Target in Ibrutinib-Resistant CLL

September 20th 2021

A genome-wide look into changes in three-dimensional chromatin organization between ibrutinib-resistant and parental chronic lymphocytic leukemia cells illustrated the involvement of PAK1 as an oncogenic driver in CLL.

Liso-cel Plus Ibrutinib Demonstrates Tolerable Safety Profile in Relapsed/Refractory CLL/SLL

September 19th 2021

Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.

Dr. Cheah on the Efficacy of TG-1701 Alone and in Combination With U2 in CLL

September 19th 2021

Chan Cheah, MBBS, discusses the results of a study evaluating the efficacy and safety of TG-1701 alone and in combination with ublituximab and umbralisib in chronic lymphocytic leukemia.

Dr. Danilov on the Efficacy of Entospletinib Plus Obinutuzumab in Relapsed/Refractory CLL

September 19th 2021

Alexey V. Danilov, MD, PhD, discusses the efficacy of entospletinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Optical Genome Mapping Offers Potential Tool to Assess Genomic Complexity in CLL

September 19th 2021

Optical genome mapping was found to effectively detect most abnormalities defined by standard methods, such as chromosome banding analysis, chromosomal microarrays, and fluorescence in situ hybridization, as well as several additional abnormalities of unknown clinical significance, in patients with chronic lymphocytic leukemia.

cfDNA-Based MRD Assessment Is Feasible, Yields Highly Concordant Results in Relapsed/Refractory CLL

September 18th 2021

The use of a cell-free DNA–based minimal residual disease assay demonstrated feasibility and highly concordant results compared with 4-color flow cytometry and improved MRD detection in patients with chronic lymphocytic leukemia who were treated with time-limited venetoclax, acalabrutinib, and obinutuzumab.

CRISPR/Cas9 and mRNA-Based Technology Allows for Gene Editing and Expression in CLL Cells

September 18th 2021

CRISPR/Cas9 and mRNA-based gene editing and expression was found to be feasible in evaluating primary chronic lymphocytic leukemia cells.

COVID-19 Continues to Result in High Admission, Fatality Rates Among Patients With CLL

September 18th 2021

COVID-19 continued to result in high admission and fatality rates among patients with chronic lymphocytic leukemia during the first 13 months of the pandemic, and although risk of severe infection was determined to be independent of age, CLL status, and treatment, being age 75 years or older was revealed to be a significant risk factor for death.

Splicing Molecule Delays Leukemic Infiltration in CLL, Has Targeted Therapy Potential

September 17th 2021

H3B-8800, a splicing molecule that binds to Splicing Factor 3b Subunit 1, has been shown to delay leukemic infiltration in a model of chronic lymphocytic leukemia using NOD-SCID interleukin-2 receptor gamma mice.

Pirtobrutinib Offers a Potential Strategy to Overcome BTK Inhibitor Resistance in CLL

September 17th 2021

Catherine Callaghan Coombs, MD, discusses the rationale for the BRUIN study, key efficacy and safety findings, and next steps with pirtobrutinib in chronic lymphocytic leukemia.

Acalabrutinib Demonstrates Improved Tolerability, Similar Efficacy to Ibrutinib in CLL

September 15th 2021

John C. Byrd, MD, discusses key findings from ELEVATE-RR, differences between acalabrutinib and ibrutinib, and future directions with the second-generation inhibitor.